Angiogenesis, in which a vascular network is established from pre-existing vessels, is a complex multistep process. Mechanisms underlying angiogenesis can be investigated using a variety of in vitro, ex vivo and in vivo approaches. Evaluation of several promising plants and plant metabolites, including terpenoids, revealed promising anti-angiogenic activity. Since the maesasaponins displayed anti-angiogenic activity in the chick chorioallantoic membrane (CAM) assay, their activity was further investigated in several test systems. The rat aorta ring assay was compared with the placental vein assay and then selected for the ex vivo investigation of the saponins. Besides their effect on the viability of HUVEC, the anti-angiogenic capacity of the compounds was also investigated in an in vivo zebrafish assay. The activity of the saponins in the viability assay was more pronounced than in the rat aorta ring assay and similar to the effect observed in the CAM assay. The use of different test systems, however, implies different results in the case of saponins.
Angiogenesis refers to the formation of a vascular network from pre-existing vessels. Besides its importance in physiological processes such as embryonic development, wound healing and menstruation, it also has a major impact in several pathophysiological conditions such as cancer, psoriasis, arthritis and retinopathy. Angiogenesis is a complex multistep process. It is characterized by early vasodilatation of a pre-existing vessel and an increase in permeability and degradation of the extracellular matrix (ECM), the latter which consists of collagen, elastin, and glycoproteins such as fibronectin and glycosaminoglycans. The loosening of the matrix allows the activated and proliferated endothelial cells (EC) to migrate and form tubes. Differentiation and stabilization of these tubes results in the formation of a vascular network [1] [2] [3] . Angiogenesis is tightly regulated with the active participation of multiple factors [2, 4] . Due to the complexity, extrapolation of in vitro and in vivo studies to the clinic remains a challenge and often requires the utilization of a combination of several experimental models. Each of these in vitro or in vivo models has their own advantages and disadvantages [5] .
In a search for new anti-angiogenic compounds, numerous plant constituents have been investigated and been shown to have activity in several test systems, thereby prompting further study. The triterpenes, comprising both steroid and triterpene saponins, contain several interesting active compounds. For instance, the maesasaponins isolated from Maesa lanceolata Forssk. var. golungensis (Myrsinaceae), display anti-angiogenic activity in the chick chorioallantoic membrane (CAM) assay ( Figure 1, table 1 ). This shrub or small tree, occurs in many African countries, and is used in traditional medicine for various indications [6] [7] [8] [9] . A mixture of maesasaponins was originally extracted from the leaves of M. lanceolata and referred to as MC3B1 [6] . Out of this mixture, fifteen maesasaponins were isolated, which were numbered according to their eluting sequence when performing semipreparative HPLC. The most abundant isolated maesasaponins were tested for their anti-angiogenic activity in the CAM assay [6] [7] [8] [9] . Thus, maesasaponins IV.2 and VI.3 were inactive; moderate activity was observed with maesasaponins I, IV.3, V.2 and VII.1; and maesasaponins II, V.3 and VI.2 displayed strong antiangiogenic activity [9] .
The anti-angiogenic properties of these compounds were subsequently evaluated using a range of assays. To study the effect of the maesasaponins in an ex vivo test several assays could be used. Since the different assays enclose their own advantages and disadvantages, the rat aorta ring assay was compared with the human placental vein assay and the effect of suramin, a known antiangiogenic compound, was tested [10] [11] [12] .
The most suitable test was selected to evaluate the activity of the saponins of interest. The effect of the saponins on the viability of Human Umbilical Vein Endothelial Cells (HUVEC) and in the zebrafish assay was also investigated. To select the most suitable ex vivo assay, angiogenesis in the rat aorta ring assay was compared with that in the placental vein assay. From days 5-13, there was no evidence of a concentrationdependent effect of serum from 0-10% FBS on the area, the number, and the length of the vascular sprouts from placental disks, (see details in supplementary Figure 1b , Table 1b ), although all increased over time. On day 20, a total absence of serum resulted in a plateauing of all parameters of vessel growth, whereas FBS concentrations of 2-10% continued to have sprout-promoting effects. The length and the number of the sprouts measured at day 20 was influenced by each concentration of serum added, compared with the addition of medium without serum. However, no difference in microvessel outgrowth was observed if 2%, 5% or 10% FBS was added. When the effect of time with 0% FBS was examined, only between days 5 and 13 could a difference be observed on the length of the sprouts. The findings were similar to those previously described, i.e., initiation of the growth of the sprouts was followed by a rapid growth phase, eventually reaching a plateau [13] .
Since a micropunch was used to produce the disks, the outline of the vessel pieces could be produced repeatedly. This might have led to a smaller standard deviation in quantification within the experiment. However, this procedure could have damaged the cells of the punch, and have led to altered microvessel outgrowth. To confirm the robustness of the findings, the same experiment was performed with human placental vein rings, which partially confirmed the cell damaging effect. The findings were similar to Figure 2b , Table 2b ) there were no serum concentration-dependent effects on vessel sprouting, although all parameters increased over time. On day 20, no further increase in vessel sprout measurements was observed in the absence of serum, whereas the presence of serum did yield an increase, particularly when 10% serum was added. No influence of time using 0% FBS was observed.
Although the results with the placental vein disks and rings appeared similar, the mean area (p = 0.0254) and number of sprouts (p = 0.0170; Student's t-test) with the ring assay was significantly larger with the disk assay (day 13 treated with 5% FBS). No difference in the length of the sprouts was detected. These differences were also observed on days 8 and 20, and with 2% FBS and 10% FBS and could be explained by the larger outline of the rings compared with the vessel piece. In contrast to the human placental veins, vessel outgrowth in the rat aorta ring assay was clearly affected by the concentration of FBS and by time (see details in supplementary Figure 3b , Table 3b ).
The relative standard deviation (RSD%) observed for the area, length and number of sprouts of all three experiments at day 13 and a treatment with 5% FBS were compared. Although no significant differences were observed between the RSD% of the experiments with the rings and disks of the human placental vein, the RSD% of the experiments with the rat aorta ring assay was lower ( Table 2 ). The identity of the EC was confirmed through the immunohistochemical detection of VWF in all three assays.
We tested the effect of suramin on angiogenesis in both the human placental vein disk assay and the rat aorta ring assay (5% FBS). At 10 and 50 µg/mL, no effect was observed. At 100 µg/mL, suramin significantly reduced the length and the number of sprouts in the placental vein disk assay, but had no effect on the area of the sprouts (see details in supplementary Figure 4b) . Similarly, only at 100 µg/mL did suramin significantly suppress all vessel growth parameters in the rat aorta ring assay (see details in supplementary Figure 5b ). Studies with the placental vein assay raised additional concerns. The prolonged use of the micropunch resulted in an experiment where only 79% of the punches initiated microvessel outgrowth. A previous report by Hornick et al. [14] revealed initiation rates of most placentas of 70-95%. Those placentas with initiation rates below 70% were excluded in their experiments. This problem would imply a need for a larger amount of test components when experiments are performed. Due to this problem and the larger variation observed in the human placental vein assay, the rat aorta ring assay was selected for all subsequent experiments.
The mixture of saponins MC3B1 inhibited microvessel outgrowth from 25 µg/mL. This effect was observed on the three parameters quantified on day 14 (Figure 2 ). Lower concentrations (0.1 µg/mL) of this mixture did not promote sprouting. Although the maesasaponin mixture (2.5 -10 µg/pellet) displayed an effect in the CAM assay [9] , anti-angiogenic activity at low concentrations could not be repeated in the rat aorta ring assay. Furthermore, the active concentration of MC3B1 within the ex vivo test corresponded with the concentration that revealed a toxic effect in the CAM assay.
Maesasaponin V.2 displayed a weak anti-angiogenic effect in the CAM assay (1 µg/pellet) [9] . However, in the rat aorta ring assay, anti-angiogenic activity was displayed on the length of the sprouts at a concentration of 25 µg/mL. The higher concentration tested (50 µg/mL) displayed an effect on all three parameters measured. Maesasaponin VI.2 was a potent angiogenic inhibitor in the CAM assay (1 µg/pellet), but failed to display the same effect in the rat aorta ring assay, since 25 µg/mL only had an effect on the area of the sprouts. At a concentration of 50 µg/mL an inhibitory effect was seen on the area, length and number of sprouts.
Maesasaponin V.3 was active on the three parameters from 25 µg/mL (details in supplementary Figure 6b ). Although this component was more potent than the previous ones, the antiangiogenic activity that was already present at low concentrations (1 µg/mL) in the CAM assay could not be confirmed in this test. The compound selected for its most promising activity in the CAM assay was maesasaponin II [9] . The concentrations tested (10 -25 µg/mL) failed to display any effect in the rat aorta ring assay. It should be noted that due to the low amounts available of this compound, only a limited number of tests could be performed (n = 4). Nonetheless, the effect was clearly different when compared with that observed in the CAM assay. Importantly, the known antiangiogenic compound -aescin displayed its activity in the rat aorta ring assay in the same concentration range (25 -50 µg/mL) as previously described [15, 16] .
The anti-angiogenic effect of the maesasaponin mixture and some of the pure maesasaponins in the zebrafish embryo assay is shown in Table 3 . The MC3B1 mix displayed toxic effects in the zebrafish assay from 25 µg/mL, but failed to show any anti-angiogenic activity at lower concentrations. Also, compound MS VI.3 failed to show any angiogenic activity in the assay, but had a toxic effect on the zebrafish embryos from 25 µg/mL. Maesasaponin II (50 µg/mL) resulted in slower development of the VP of one of the zebrafish embryos, but failed to show anti-angiogenic activity on the rest of the embryos (Figure 3 ). Lower concentrations of the component displayed no anti-angiogenic activity, while a concentration of 75 µg/mL was lethal. Ginsenoside Rb1 (1 -50 µg/mL), known for its influence on angiogenesis [17, 18] , was not active in this assay.
The effect of different saponins on HUVEC viability was examined. As shown in Figure 4 , a clear effect of the maesasaponin mixture MC3B1, aescin and maesasaponin V.3 could be observed from 10 µg/mL. Maesasaponin V.2 failed to show any activity at 10 µg/mL. Here, the maesasaponins, which displayed anti-angiogenic activity in the CAM assay, were further investigated in several test systems. For the selection of the most appropriate ex vivo test, the human placental vein assay was compared with the rat aorta ring assay. Several differences were observed between these tests, and suramin 100 µg/mL displayed a limited effect in the placental vein disk assay, which might be explained by the larger variation observed in the placental vein assay. Previously, considerable variations were observed between treated cultures, depending on the donor of the placenta. Also, the effect of an anti-VEGF antibody was variable in the cultures of the same patient [13] .
Since the variability in the rat aorta ring assay was less when compared with the placental vein assay, this test was selected for the ex vivo investigation of a limited number of saponins. All maesasaponins were potent angiogenesis inhibitors at a concentration of 10 µg/pellet in the CAM assay [9] . The maesasaponin mixture (2.5 -10 µg/pellet), maesasaponin II, V.3 and VI.2 (all 1 µg/pellet) displayed a potent anti-angiogenic effect in the CAM assay, while maesasaponin V.2 (1 µg/pellet) was only weakly active [9] . This pronounced and weak activity of the respective components, found before, was not observed at the same concentration range in the rat aorta ring assay. Here, an effect could only be observed at 25 or 50 µg/mL. Also, aescin (1 µg/pellet) exhibited weak activity in the CAM assay, but failed to show the same effect in the rat aorta ring assay, where it was active at 25 -50 µg/mL. The activity in this concentration range in the latter test system has already been published [15] and was confirmed in our experiments. Results from these experiments indicate possible differences in sensitivity for saponins in both the rat aorta ring assay and CAM assay.
The anti-angiogenic capacity of some compounds was also investigated in the in vivo zebrafish assay. However, none of the saponins showed anti-angiogenic activity. Also, ginsenoside Rb1, which is known for its activity on angiogenesis, failed to show any activity in the zebrafish assay [17] . Since some saponins are known for their toxic effect on fish, the suitability of this test for measuring anti-angiogenic activity of saponins could be questioned.
Finally the effect of several compounds on the viability of HUVEC was investigated. The maesasaponin mixture, maesasaponin V.3 and aescin showed an effect at 10 µg/mL, while maesasaponin V.2 failed to show any effect at 10 µg/mL. It appeared that the activity of the saponins was more pronounced when compared with the rat aorta ring assay and similar to the effect observed in the CAM assay.
Although the effect of maesasaponin II on the viability of HUVEC was not tested, we also would expect a more pronounced effect compared with the activity in the rat aorta ring assay.
Since growth factors were present in both tests, resulting in a more pronounced effect of the saponins, and absent in the rat aorta ring assay, the activation of the HUVEC by the growth factors might be important in the sensitivity of the cells for the saponins and the antiangiogenic effect of the compounds. Although the mechanism resulting in the angiogenic effect of the maesasaponins still should be investigated, this study contributes to the knowledge on the structure activity relationship of saponins in angiogenesis.
